Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS3610a in Advanced Solid Tumors
NCT07159126Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of DS3610 in solid tumor, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Dose Limiting Toxicities at 24 months. Started Oct 2025; status: recruiting.
02
Drugs
DS3610
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07159126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07159126.